How to Sequence Medical Device Market Entry in Latin America
A four-market entry playbook for Brazil, Mexico, Argentina, and Colombia: separate national registrations, BGMP and equivalence branch points, local licence-holder choices, reference-approval leverage, and different filing sequences for FDA-backed and CE-only portfolios.
Regional verdict
Latin America is not one coordinated registration system: Brazil, Mexico, Argentina, and Colombia each classify, review, issue, and renew their own authorization. Brazil is the heaviest market because Class III/IV Registro is gated by BGMP and a mandatory Brazil Registration Holder (BRH). Mexico is the most structurally flexible, combining Mode C holder options with a legacy equivalence agreement and a newer abbreviated route. Argentina has materially deregulated low-risk entry in 2025–2026 through a reference-country sworn-declaration route, while Colombia still operates under its current Decreto 4725/2005 framework as a broader reform remains pending. The practical value is therefore not a fictional regional filing: it is sequencing the four national filings from the easiest route your existing approvals unlock to the hardest one they do not.
Standard pathway flow
The four markets share a five-step planning shape, but the decisive branch points are Brazil BGMP and each country’s reference-approval rules.
1. Classify in each country
Map the device independently into Brazil Class I–IV, Mexico Clase I–III, Argentina Clase I–IV, and Colombia Clase I/IIa/IIb/III. Do not carry a foreign class across automatically: the class determines notification versus full review, and in Brazil it determines whether BGMP becomes a certificate gate.
2. Inventory reference approvals and choose the branch
Separate FDA, Health Canada, TGA, Japan, CE, NMPA, and MDSAP evidence rather than treating them as interchangeable. Test Brazil AREE eligibility, Mexico’s applicable equivalence or abbreviated mechanism, and Argentina’s Decreto 892/25 low-risk reliance route; keep Colombia on the standard route because no formal reference-approval fast track was confirmed.
3. Lock the licence-holder structure before the dossier
Appoint the Brazil BRH, choose Mexico’s manufacturer-as-Titular or local-Titular structure, appoint Argentina’s Importador Autorizado with a Director Técnico, and select Colombia’s Titular del Registro. Put dossier custody and transfer cooperation into the contract before filing.
4. Submit, with BGMP and equivalence workstreams in parallel
File the national dossier through the appointed holder. In Brazil Class III/IV, run BGMP certification in parallel because final Registro approval is conditioned on it; use MDSAP evidence where available. In Mexico and eligible low-risk Argentina filings, assemble the qualifying foreign approval and identity/free-sale evidence for the selected reliance route instead of assuming it will be applied automatically.
5. Issue, import, and maintain country-specific obligations
After authorization, keep the holder’s establishment licence, local-language labels, shipment-level import permissions, post-market reporting, renewals, and change filings current. The four certificates remain separate assets with separate transfer and supply-continuity risks.
License-holder arrangements
Brazil, Argentina, and Colombia are Mode B local-holder markets; Mexico is the region’s Mode C exception. Across the four, the same three-way structuring choice still recurs, but Mexico lets the foreign manufacturer retain the Registro Sanitario in its own name through a local legal representative.
Own subsidiary as holder
Use a manufacturer-owned local entity as BRH, Importador Autorizado, or Titular. This gives the strongest certificate and dossier control, but requires entity formation plus the relevant AFE/Habilitación/CCAA, qualified personnel, and continuing compliance overhead. Mexico can achieve manufacturer Titular control without necessarily incorporating locally, so the entity case is weaker there.
Distributor or importer as holder
This is usually the fastest, lowest-upfront-cost launch because the local party already has import and compliance infrastructure. It also gives the commercial counterparty control of the certificate in Brazil, Argentina, and Colombia; transfer depends on formal filings and outgoing-holder cooperation. Mexico does not require this concession because manufacturer-as-Titular is available.
Independent regulatory holder or legal representative
A neutral BRH, specialist import agent, or regulatory-services Titular separates certificate control from distribution. In Mexico, the cleanest variant is the foreign manufacturer as Titular with a Mexico-based legal representative holding a Licencia Sanitaria. The added annual service fee buys easier distributor changes and reduces certificate-custody leverage.
The structural breakpoint is Mexico Mode C: the manufacturer may hold the Registro Sanitario itself through a Mexican legal representative. Brazil always requires a BRH; Argentina always requires an Importador Autorizado plus Director Técnico; Colombia always requires a Colombia-based Titular del Registro. In those three Mode B markets, the three-way choice changes who controls the local holder, not whether a local holder is required.
Reference-certificate leverage
- Brazil: the formal RDC 741/2022 / IN 290/2024 AREE route for Class III/IV recognizes exactly US FDA, Health Canada, Australia TGA, and Japan MHLW/PMDA. CE is explicitly excluded, as is NMPA; CE document reuse is not the same as formal reliance.
- Mexico: the legacy 2010/2012 Acuerdo de Equivalencia recognizes FDA, Health Canada, and Japan, not CE. The Vía Regulatoria Abreviada took effect on 1 September 2025 with a 30-business-day target and separate eligibility tests. An industry report also says NMPA marketing authorizations entered the regulatory-equivalence framework from September 2025 with Class I/II/III targets of 20/25/35 business days; 【pending direct verification of the official instrument, original text, its mapping to the Vía, and CE enumeration under the Vía】.
- Argentina: Decreto 892/25 names the United States, EU, United Kingdom, Japan, Australia, Israel, and EFTA member states. For Clase I/II devices and non-cold-chain IVD Clase A/B, a qualifying free-sale certificate unlocks a sworn-declaration notification and exemption from local testing; Clase III/IV remain under full review.
- Colombia: no currently operative formal FDA/CE fast track was confirmed. CE and FDA files reduce original evidence work and Requerimiento rounds inside the standard review, but a separately named “Registro Sanitario Simplificado” with a compressed clock remains 【unverified】; the pending unified decree is not yet in force.
- MDSAP has a separate site-level value in Brazil: it can support waiver of ANVISA’s own BGMP on-site inspection and extends BGMP validity from 2 to 4 years. The 2026–2027 agenda proposal to make MDSAP the principal foreign-manufacturer BGMP route is 【a proposal, not effective law; direct official verification remains pending】.
Suggested entry sequence
Mexico → Argentina → Colombia → Brazil. Mexico offers the legacy FDA equivalence basis and the separately eligible abbreviated route; low-risk Argentina can use Decreto 892/25; Colombia reuses the FDA file within standard review; Brazil comes last because FDA unlocks AREE but does not remove BRH, BGMP, Portuguese, or the heavy Class III/IV Registro workload.
Argentina → Colombia → Mexico → Brazil. Eligible low-risk Argentina filings receive the clearest formal CE benefit; Colombia can reuse the full CE technical file inside standard review; Mexico’s older equivalence agreement excludes CE and CE eligibility under the newer Vía remains unconfirmed; Brazil is the hard stop because CE does not unlock AREE at all, leaving the full Class III/IV Registro plus BGMP path.
Country-by-country delta table
| Country | Regulator | Registration form | Licence holder mode | Validity | Key special requirement |
|---|---|---|---|---|---|
| Brazil | ANVISA | Notificação (Cadastro), Class I/II; Registro, Class III/IV | Mode B — mandatory AFE-holding Brazil Registration Holder (BRH) | Cadastro indefinite; Registro 10 years; BGMP 2 years or 4 years with current MDSAP | Class III/IV BGMP gate; Portuguese labelling; INMETRO/ANATEL where applicable; AREE excludes CE |
| Mexico | COFEPRIS | Aviso for eligible low risk; Registro Sanitario, standard/equivalence/abbreviated routes | Mode C — manufacturer may be Titular via a Mexican legal representative, or a local importer/distributor may hold it | Initial Registro 5 years; 10-year Prórroga treatment after the April 2026 reform 【device-specific applicability pending direct confirmation】 | Spanish labelling; NOM-241 GMP; identity tests for the Vía; September 2025 NMPA equivalence details remain flagged |
| Argentina | ANMAT / INPM | Declaración Jurada for eligible low risk; Certificado de Registro via HELENA for standard/full review | Mode B — mandatory Importador Autorizado with a Director Técnico | Certificado de Registro 5 years; sworn declaration has no fixed expiry but changes must be re-declared within 30 days | Traductor Público translation plus Apostille; Decreto 892/25 reliance only for Clase I/II and non-cold-chain IVD A/B; reform transition not fully settled |
| Colombia | INVIMA | Registro Sanitario for all classes; automatic for Class I and some IIa, full review for IIb/III | Mode B — mandatory Colombia-based Titular del Registro | 10 years; renewal at least 90 days before expiry | Spanish dossier/label; CCAA for storage/conditioning; shipment VUCE permit; formal FDA/CE fast track remains unconfirmed and the reform is not in force |
Common pitfalls
- BRH transfer freeze: an uncooperative outgoing Brazil BRH can stall a holder transfer and freeze imports for 6–12 months; BGMP certification is also linked to the requesting Brazilian company and generally does not transfer automatically.
- The CE-to-Brazil misconception: CE technical documentation can be reorganized and reused, but CE does not qualify for Brazil’s formal AREE route and does not remove the Class III/IV BGMP gate.
- Treating Argentina’s new rules as fully settled: Decreto 892/25 creates a real low-risk reliance route, but the Mercosur-wide entry-into-force status of Disposición 64/2025, the route’s fixed processing time, and other reform transition details retain explicit verification flags.
- Ignoring shipment release and inspection clocks: Brazil BGMP inspection queueing and shipment-level import licensing, Colombia’s per-shipment VUCE permit, and country-specific authentication/label workstreams can pace supply even after the core dossier is ready.
Explore the country pages
Each row links to the full country regulatory report for registration pathway, timeline, cost, and post-market obligations.